AbbVie Inc. (ABBV) Q4 2025 (USD): Adj. EPS 2.71 (exp. 2.65), Revenue 16.6bln (exp. 16.41bln); Q4 results include unfavourable impact of 0.71/SHR related to acquired IPR&D and milestones expense

AbbVie reported Q4 earnings that topped expectations for both adjusted EPS and revenue, indicating stronger operational performance.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

US BROKER MOVES: NET upgraded at BTIG; LUMN downgraded at Raymond James

UAE's ADNOC sets its March Murban crude OSP at USD 63.99/bbl

AbbVie Inc. (ABBV) Q4 2025 (USD): Adj. EPS 2.71 (exp. 2.65), Revenue 16.6bln (exp. 16.41bln); Q4 results include unfavourable impact of 0.71/SHR related to acquired IPR&D and milestones expense

Phillips 66 (PSX) CEO says don't have upstream capability, so we won't be going into Venezuela to help that development - CNBC Interview

US PRE-MARKET MOVERS: AMD, NVDA, SLAB, ENPH, SMCI, LLY, TTWO, GEHC, CTVA, MDLZ, CMG, COR, UBER

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

Drug Breakdown:

  • Skyrizi 5.01bln
  • Rinvoq 2.37bln (exp. 2.41bln)
  • Humira 1.25bln

Guidance:

  • FY26 adj. EPS view 14.37-14.57 (exp. 14.22).
Context

However, the unfavorable impact related to acquired in-process R&D and milestones may raise some concerns about future expenses. This result could bolster sentiment in the biotech sector, yet investors should watch the guidance closely, as it suggests further stability even amidst product-specific challenges.

Related headlines

The whole workspace, free to try.

Try it free